Table 2.
Participant characteristics.
| Study | Groups | N | Age (mean baseline) | M BMI Pre (kg/m2) | Duration of amenorrhea (months) | Duration of AN (months) | Diagnostic criteria | Weight gain strategies | Change in BMI or Weight |
|---|---|---|---|---|---|---|---|---|---|
| Bloch 2012 | AN - DHEA AN - Placebo |
15 11 |
26.6 | 17.75 | DSM-IV | Ongoing psychotherapy which included weekly individual dynamic psychotherapy and group cognitive/supportive psychotherapy + nutritional assessment | NS change in BMI | ||
| DiVasta 2012 | AN - DHEA + OC AN - Placebo |
31 29 |
18 18.3 |
18.1 17.8 |
11 | 12 | Participants were enrolled in outpatient therapy for an ED at Boston children’s hospital. | Among trial completers, 5 lost weight (1.4–5.3 kg), 1 subject showed no change, and the remainder gained up to 21.7 kg. | |
| Fazeli 2014 | AN - TPT AN - Placebo |
10 11 |
47 47 |
17.6 16.6 |
N = 8 N = 7 |
292.8 216 |
|||
| Golden 2002 | AN - EE/progestin AN - Treatment controls |
22 28 |
17.5 16.3 |
17.1 16.7 |
16.5 | 29.8 | DSM-IV | All subjects were in outpatient treatment for EDs. | |
| Golden 2005 | AN - Alendronate AN - Placebo |
15 17 |
16.9 16.9 |
16.3 16.4 |
20.1 19.9 |
25.7 34.7 |
DSM-IV | 15 of 29 subjects achieved a weight 85% of standard body weight | |
| Gordon 1999 | AN - DHEA | 15 | 17.3 | 17.3 | 20.9 | 29.1 | DSM-IV | Subjects enrolled in ED program in Boston Children’s Hospital | NS change in BMI |
| Grinspoon 1996 | AN - rhIGF1 100 μg AN - rhIGF1 30 μg |
23 | 23 | 16.3 | 22 | 60 | DSM-IV | NS change in BMI | |
| Grinspoon 2002 | AN - rhIGF-1 AN - Placebo |
29 30 |
25.6 | 16.9 16.3 |
DSM-IV | NS change in BMI | |||
| Iketani 2003 | AN - MED + AN - MED− HC |
10 11 12 |
22.1 21.3 22.2 |
13.6 13.7 19.6 |
3.6 yr 3.5 yr |
3.9 yr 4.1 yr |
DSM-IV | Sig. increase in BMI in both groups, no differences between groups | |
| Karlsson 2000 | AN - ERT AN - No treatment AN - Recovered HC |
58 77 26 205 |
28.4 25.9 27.3 27.3 |
15.4 15.6 20.3 23.1 |
4.5 yr 5.4 yr 3.5 yr |
ICD-10 | |||
| Misra 2009 | AN - rhIGF1 AN - Placebo |
10 10 |
16.2 16.3 |
17.2 17.5 |
6.1 9 |
DSM-IV | NS change in BMI | ||
| Misra 2011 | AN - E + AN - E− HC |
31 30 29 |
16.5 15.6 |
17.4 21.4 |
0.9 yr | DSM-IV | All girls with AN were under the care of multidisciplinary treatment teams organized by their primary providers. | ||
| Miller 2011 | AN - Risedronate-Testosterone AN - Risedronate AN - Testosterone AN - Placebo |
20 20 19 18 |
25.2 25.3 27.1 26.9 |
17.8 17.6 17.5 17.9 |
6.3 5.1 6.6 5.2 |
DSM-IV | Sig increases in weight in both groups, no differences across groups. | ||
| Miller 2004 | AN - Risedronate AN - control |
10 14 |
28.6 26.9 |
44 kg 42 kg |
33 23 |
DSM-IV | No sig increase in BMI in exp. group, but control group BMI sig. Increased at 9 months (p < 0.01) | ||
| Miller 2005 | AN - testosterone AN - Placebo |
24 9 |
25 22 |
16.9 16.6 |
DSM-IV | NS change in BMI | |||
| Munoz - Cavalo 2007 | AN-E + AN - E− HC |
10 10 19 |
15.4 | Sig. increase in BMI in Group 2 (patients with AN for < 1 yr) | |||||
| Seeman 1992 | AN OC AN OC-HC Primary amenorrhea |
37 16 52 12 |
24.4 | 17.2 ± 0.8 | 66.5 ± 15.5 | DSM- III- R | NS difference in BMI across groups (cross-sectional) | ||
| Shibli-Rahhal 2012 | AN TPt | 1 | 52 | 14.3 | 4 yr | 72 | Weight restored prior to treatment. NS change in BMI following TPt. | ||
| Strokosch 2006 | AN - NGM/EE AN - Placebo |
53 59 |
15.2 15.1 |
17.94 | 9.7 (m) | DSM-IV | NS change in BMI |
Baseline participant characteristics. AN = Anorexia Nervosa, HC= Healthy Controls, BMI =Body Mass Index, Tpt= teriparatide, EE =ethinyl estradiol, ERT =estrogen replacement therapy. NGM = Norgestimate, OC = oral contraceptives, MED= Menatetrenone.